Novo Nordisk Rybelsus Superior Reduction In Cardiovascular Events In Trial

 

• SOUL study showed Rybelsus® (semaglutide) tablets 14 mg reduced the risk of major adverse cardiovascular events (MACE) by 14% (ARR 2% absolute risk reduction at 3 years) vs placebo in adults with type 2 diabetes and atherosclerotic cardiovascular disease (ASCVD) and/or chronic kidney disease (CKD)1
• Oral semaglutide 14 mg demonstrated this reduction of risk on top of standards of cardiovascular (CV) and diabetes care
• Data simultaneously published today in The New England Journal of Medicine, and based on SOUL findings, Novo Nordisk submitted a label extension application for Rybelsus® (semaglutide) tablets 14 mg for CV event risk reduction to the FDA

https://www.prnewswire.com/news-releases/oral-semaglutide-14-mg-demonstrated-superior-reduction-in-risk-of-cardiovascular-events-in-late-breaking-soul-trial-presented-at-the-american-college-of-cardiology-302414854.html